Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1815||SWOG||A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1820||SWOG||A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)||Cancer Prevention and Control CIRB||Available to Open|
|S1823||SWOG||A Prospective Observational Cohort Study To Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors||Cancer Prevention and Control CIRB||Available to Open|
|S1826||SWOG||A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patient (Age >/= 12 Year) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1827||SWOG||MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1900A||SWOG||A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1900B||SWOG||A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1900C||SWOG||A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1905||SWOG||A Phase I/II Study of AKR1C3-Activated Prodrug OBI‐3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1914||SWOG||A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|